Prostate cancer nursing: assessment, treatment, and post-op care

Prostate cancer is the most common non-skin malignancy in men in the United States, with approximately 300,000 new diagnoses annually. The majority of cases are adenocarcinomas arising in the peripheral zone of the gland, and most are detected at a localized stage through PSA screening before any symptoms develop. Because the disease spans a wide biological spectrum — from slow-growing tumors that may never require treatment to aggressive metastatic disease — nursing care demands fluency with risk stratification, the rationale behind divergent treatment pathways, and the specific post-treatment complications that nursing students consistently encounter on NCLEX.

Prostate cancer staging quick reference

Pathophysiology and Gleason grading

Prostate anatomy and tumor origin

The prostate is a walnut-sized exocrine gland surrounding the urethra at the bladder neck. It is divided into three principal zones:

• Peripheral zone — accounts for ~70% of glandular tissue and is the origin of ~75% of prostate cancers. Palpable on digital rectal examination (DRE).
• Transition zone — surrounds the urethra and is the site of benign prostatic hyperplasia (BPH). Approximately 20–25% of cancers arise here and are typically detected on TURP specimens.
• Central zone — surrounds the ejaculatory ducts; rarely the source of primary malignancy but can be invaded by transition or peripheral zone tumors.

More than 95% of prostate cancers are adenocarcinomas — malignant transformation of the secretory ductal epithelial cells that produce prostate-specific antigen (PSA). Less common histologies include ductal adenocarcinoma, small cell neuroendocrine carcinoma (poorly PSA-secreting; aggressive), and squamous cell carcinoma.

Gleason score and Grade Group system

The Gleason score quantifies tumor architecture under microscopy. A pathologist assigns a primary pattern (most prevalent) and a secondary pattern (second most prevalent), each graded 3 through 5:

• Pattern 3 — well-formed, distinct glands; lowest aggression
• Pattern 4 — poorly formed, fused, or cribriform glands; intermediate aggression
• Pattern 5 — no glandular differentiation, sheets or single cells; highest aggression

The two scores are summed to give the Gleason score (range 6–10). Because Gleason scores 2–5 are essentially never reported on modern needle biopsies, clinically meaningful scores run from 6 to 10.

The 2014 ISUP Grade Group system translates Gleason scores into a cleaner 1–5 scale with direct prognostic implications:

The distinction between 3+4 and 4+3 is clinically significant: both sum to 7, but the dominant pattern determines the Grade Group and shifts management — 4+3 is a Grade Group 3 tumor that frequently warrants treatment rather than active surveillance.

PSA biology

PSA is a serine protease produced almost exclusively by prostate epithelial cells; its physiologic role is liquefaction of seminal coagulum. In serum, PSA circulates in free and protein-bound fractions.

• Normal: <4 ng/mL (though population-specific cutoffs exist; younger men warrant concern at lower levels)
• Grey zone: 4–10 ng/mL — approximately 25% of men in this range have prostate cancer on biopsy; free PSA percentage helps discriminate (free PSA >25% favors BPH; <10% favors malignancy)
• PSA density: PSA divided by prostate volume on MRI; >0.15 ng/mL/cc is considered elevated

PSA elevation is not diagnostic — it can be raised by BPH, prostatitis, perineal trauma, and ejaculation within 48 hours. Biopsy is required to establish the diagnosis.

Diagnostics and clinical presentation

Screening

The American Cancer Society recommends shared decision-making regarding PSA screening:

• Age 50 for men at average risk with ≥10-year life expectancy
• Age 45 for men at high risk (African American men; first-degree relative diagnosed before age 65)
• Age 40 for men at very high risk (more than one first-degree relative with early prostate cancer)

DRE detects palpable nodules or induration in the peripheral zone. A hard, irregular nodule warrants biopsy regardless of PSA level.

Biopsy techniques

Transrectal ultrasound (TRUS)-guided biopsy is the traditional standard — 12 systematic cores are sampled from the peripheral and transition zones. Its limitation is that ultrasound cannot reliably delineate tumor margins.

MRI-targeted (fusion) biopsy uses pre-biopsy multiparametric MRI (mpMRI) to identify PI-RADS 3–5 lesions, which are then registered to real-time TRUS images for precise targeted sampling alongside systematic cores. Fusion biopsy improves clinically significant cancer detection and reduces overdetection of low-grade disease.

Clinical presentation

Localized prostate cancer is characteristically asymptomatic. Symptoms develop only when the tumor reaches a size or position that disrupts adjacent structures:

• Lower urinary tract symptoms (frequency, nocturia, weak or hesitant stream, incomplete emptying) indicate local extension into the transition zone or urethral compression — findings more commonly associated with BPH but warranting evaluation
• Hematuria or hematospermia may reflect tumor invasion of the urethra or seminal vesicles
• Erectile dysfunction can result from neurovascular bundle involvement
• Bone pain (back, hips, pelvis) is the hallmark of skeletal metastases — the most common site of distant spread (axial skeleton via Batson venous plexus)
• Pathologic fracture or spinal cord compression are emergencies in metastatic disease requiring urgent imaging and intervention

Like UTI nursing and pyelonephritis, early prostate cancer rarely produces obvious urinary symptoms — the absence of symptoms should never reassure a nurse that cancer is absent.

Staging workup

After diagnosis, additional imaging guides staging:

• Bone scan (technetium-99m) — identifies osteoblastic skeletal metastases; indicated for PSA >20, Gleason ≥8, T3–T4, or symptoms
• CT abdomen/pelvis — lymph node assessment; limited sensitivity for small nodal metastases
• PSMA PET/CT (prostate-specific membrane antigen) — highly sensitive and specific for nodal and distant metastases; increasingly first-line for high-risk and biochemical recurrence staging; superior to bone scan + CT for metastatic burden assessment
• MRI pelvis — local staging (extracapsular extension, seminal vesicle invasion, neurovascular bundle)

Treatment by risk category

Active surveillance

For low-risk and selected favorable-intermediate-risk disease, active surveillance defers treatment while monitoring for disease progression. The standard protocol includes:

• PSA every 6 months
• DRE annually
• Repeat biopsy (or mpMRI surveillance) at 1 year, then every 2–5 years
• Treatment triggered by PSA kinetics (doubling time <3 years), Grade Group upgrade on repeat biopsy, or patient preference change

Active surveillance is not “watchful waiting” (a palliative approach used in elderly patients with competing comorbidities). It is an active, protocol-driven monitoring strategy with curative intent preserved.

Radical prostatectomy

Radical prostatectomy (RP) removes the entire prostate gland, seminal vesicles, and typically pelvic lymph nodes (bilateral pelvic lymph node dissection). Approaches:

• Open retropubic RP — the historical standard; large incision, good tactile feedback
• Laparoscopic RP — minimally invasive; reduced blood loss but technically demanding
• Robot-assisted laparoscopic prostatectomy (RALP) — now the dominant approach in the US; 3D visualization, wristed instrument movement, shorter hospital stay (1–2 days), reduced blood loss

Nerve-sparing technique preserves the neurovascular bundles along the posterolateral prostate, reducing but not eliminating risk of erectile dysfunction.

Radiation therapy

External beam radiation therapy (EBRT), typically intensity-modulated (IMRT), delivers fractionated doses over 4–9 weeks. Hypofractionation (fewer but larger doses) and stereotactic body radiotherapy (SBRT) are increasingly used for localized disease.

Brachytherapy involves implanting radioactive seeds directly into the prostate:

• Low-dose rate (LDR) — permanent iodine-125 or palladium-103 seeds; outpatient procedure
• High-dose rate (HDR) — temporary high-activity iridium-192 catheters; delivers radiation in one or more fractions, then removed

Androgen deprivation therapy

Since testosterone drives prostate cancer proliferation, reducing androgens to castrate levels (<50 ng/dL) produces disease control across risk groups and stages. ADT is covered in depth in the nursing priorities section below.

Systemic therapies

Chemotherapy: Docetaxel (every-3-week IV) is the backbone of chemotherapy for metastatic castration-sensitive prostate cancer (mHSPC) and mCRPC. Cabazitaxel is used in the post-docetaxel mCRPC setting.

PARP inhibitors: Olaparib and rucaparib target homologous recombination DNA repair deficiencies; approved for mCRPC with BRCA1/2 or other HRR gene mutations.

Immunotherapy: Sipuleucel-T (Provenge) is an autologous dendritic cell vaccine approved for minimally symptomatic or asymptomatic mCRPC. The patient’s own antigen-presenting cells are harvested via leukapheresis, activated ex vivo against prostatic acid phosphatase (PAP) antigen, and re-infused over three infusions two weeks apart.

The oncology nursing principles that apply here — monitoring for cytopenias, infusion reactions, fatigue — overlap with concepts covered in leukemia nursing and lymphoma nursing.

Nursing priorities: radical prostatectomy

Late complications to monitor

Anastomotic stricture can develop weeks to months after RP as the urethrovesical anastomosis heals with fibrosis. Presentation: progressive urinary hesitancy, decreased stream force, or complete urinary retention. Management requires urethral dilation or internal urethrotomy. Nurses should include this in discharge counseling so patients recognize symptoms and seek timely evaluation.

Biochemical recurrence is detected at the first follow-up PSA (6–8 weeks post-RP). The PSA nadir after radical prostatectomy should approach or reach undetectable (<0.1 ng/mL). A PSA that fails to nadir or subsequently rises to ≥0.2 ng/mL on two consecutive measurements defines biochemical recurrence and triggers restaging.

Nursing priorities: radiation therapy

Radiation affects rapidly dividing cells throughout the treatment field. Urinary and rectal tissues in the low pelvis are particularly sensitive.

Urinary side effects

Acute radiation cystitis produces urinary urgency, frequency, dysuria, and nocturia, typically beginning 2–3 weeks into a course of EBRT and resolving weeks to months after treatment:

• Encourage 8–10 glasses of water daily to dilute urine and reduce bladder irritation
• Advise patients to avoid caffeine, alcohol, and citrus juices (bladder irritants)
• Alpha-blockers (tamsulosin) may be prescribed to relax the bladder neck and reduce LUTS
• Assess for hematuria — mild spotting is common; gross hematuria with clots warrants investigation
• Patients with LDR brachytherapy seeds should be counseled to strain urine in the first weeks to detect any passed seeds; sex partners of childbearing age should limit prolonged close contact for a defined period per radiation safety protocol

Rectal side effects

Radiation proctitis produces diarrhea, rectal urgency, tenesmus, and rectal bleeding due to radiation exposure to the anterior rectal wall:

• Institute a low-residue diet during treatment (white rice, refined bread, cooked vegetables without skins) to reduce stool bulk and rectal distension
• Antidiarrheals (loperamide) PRN for loose stools
• Sitz baths for rectal discomfort; avoid stool straining
• Assess perianal skin for radiation dermatitis
• Rare late complication: radiation proctitis with chronic bleeding or fistula — refer to gastroenterology

Fatigue

Radiation-related fatigue is cumulative and often most pronounced in weeks 3–6 of treatment. It is multifactorial (cytokine release, anemia, sleep disruption, treatment burden). Nursing interventions include energy conservation strategies, scheduled rest, light aerobic exercise (shown in studies to reduce cancer-related fatigue), and screening for treatable contributors including anemia and depression.

Sexual side effects

Radiation can damage neurovascular bundles and reduce penile blood flow over time. Erectile dysfunction may manifest or worsen months to years after treatment — a delayed presentation compared with post-RP ED. Counsel patients that sexual side effects may not be immediately apparent and that PDE-5 inhibitors are effective in many men.

Nursing priorities: ADT/hormone therapy

Managing systemic ADT side effects

Hot flashes are the most consistently reported ADT side effect, affecting up to 80% of men on castration therapy. They result from disrupted thermoregulatory set-point secondary to estrogen/testosterone withdrawal. Non-pharmacologic interventions (layered clothing, cool environments, reducing spicy foods and alcohol) help. Pharmacologic options include venlafaxine (SNRI, modest effect), medroxyprogesterone acetate, and cyproterone acetate. Hot flashes are a physiologic castration side effect — not a sign of infection or fever.

Bone health is a priority for all patients on long-term ADT. Testosterone deficiency accelerates bone resorption, increasing fracture risk. Nursing actions:

• Initiate calcium 1,200 mg/day (dietary or supplemental) and vitamin D 800–1,000 IU/day at ADT start
• Obtain baseline DEXA scan and repeat every 1–2 years
• Refer to bone-protective pharmacotherapy (denosumab or zoledronic acid) for T-score ≤ −2.5 or fragility fracture

Cardiovascular risk is elevated with ADT. Metabolic syndrome (visceral adiposity, dyslipidemia, insulin resistance, hypertension) develops in a significant proportion of men within 3–6 months of starting castration therapy. The FDA issued a class label warning for increased risk of MI, stroke, and sudden cardiac death. At each visit, screen for: weight gain, BP, fasting glucose, lipid panel. Encourage aerobic exercise and dietary modification.

Gynecomastia (breast tissue enlargement, breast tenderness) results from the peripheral aromatization of adrenal androgens to estrogen in the absence of testosterone. Prophylactic low-dose breast irradiation or tamoxifen can be offered at ADT initiation.

Psychosocial impact is substantial. Depression, anxiety, sexual dysfunction, and body image concerns are common with ADT. Screen using validated tools (PHQ-9); refer to oncology social work, counseling, or support groups as appropriate. This mirrors psychosocial considerations in breast cancer nursing and colorectal cancer nursing, where treatment side effects significantly affect quality of life.

Systemic chemotherapy nursing considerations

Docetaxel: Premedicate with oral dexamethasone 8 mg the evening before, morning of, and evening after infusion to reduce hypersensitivity reactions and fluid retention. Monitor CBC before each cycle (nadir day ~8–10). Nadir neutropenia is the most dangerous complication — teach signs of febrile neutropenia (temperature ≥38.3°C with ANC <500). Peripheral neuropathy and alopecia are common.

Olaparib (PARP inhibitor): Indicated for mCRPC with BRCA1/2 or other homologous recombination repair mutations (determined by tumor or germline testing). Monitor CBC monthly — cytopenias (anemia, thrombocytopenia) are the primary toxicity. Dose reduction or interruption for Grade 3–4 hematologic toxicity. Contraindicated in pregnancy (teratogenic). Alert patients to fatigue, nausea, and pneumonitis risk.

These cytotoxic nursing responsibilities align with broader oncology principles discussed in lung cancer nursing and acute kidney injury monitoring during nephrotoxic regimens.

Monitoring and biochemical recurrence

Post-treatment PSA monitoring

The PSA response after treatment defines success and signals recurrence:

After radical prostatectomy: PSA should become undetectable (<0.1 ng/mL) within 4–6 weeks because the prostate — the only significant PSA-producing tissue — has been removed. A persistently detectable PSA after RP suggests either residual local disease or occult metastatic disease.

After radiation therapy: PSA declines slowly over 18–36 months to a nadir. The Phoenix definition of radiation failure is PSA rise of 2 ng/mL above the nadir. PSA bounce (transient rise without progression) can occur after brachytherapy and should not be confused with recurrence.

On ADT: PSA declines toward nadir as testosterone is suppressed. Castration-resistant prostate cancer (mCRPC) is defined as PSA progression (≥25% rise above nadir, minimum +2 ng/mL rise) despite serum testosterone at castrate levels (<50 ng/dL). At this point, additional androgen-pathway inhibitors, chemotherapy, or targeted agents are introduced.

Biochemical recurrence after RP

Definition: PSA ≥0.2 ng/mL on two consecutive measurements after radical prostatectomy. This occurs in approximately 20–40% of patients within 10 years.

Clinical significance: Biochemical recurrence precedes clinical recurrence by months to years. Management depends on restaging (PSMA PET is now first-line): local recurrence in the prostate bed is treated with salvage radiation; nodal or distant disease may require systemic therapy.

Metastatic castration-resistant prostate cancer (mCRPC)

mCRPC is defined by:

1. Castrate serum testosterone (<50 ng/dL) — patient is on ADT
2. PSA progression or radiographic progression

Despite castration levels, the tumor has developed mechanisms of androgen receptor reactivation (AR amplification, mutations, splice variants like AR-V7). First-line options include enzalutamide, abiraterone, docetaxel, or combinations thereof. PARP inhibitors are introduced for patients with HRR mutations. The nurse’s role focuses on managing compounding side effects as additional lines of therapy are added and monitoring for skeletal events, pain, and functional decline.

Principles of renal function monitoring during nephrotoxic systemic therapy — relevant to AKI nursing and CKD/ESRD nursing — apply here, as contrast imaging and some chemotherapy agents can compromise kidney function.

NCLEX tips

1. PSA elevation alone does not diagnose prostate cancer. PSA can be elevated by BPH, prostatitis, recent DRE, or ejaculation within 48 hours. Tissue biopsy is required for diagnosis.

2. Gleason 3+4=7 (Grade Group 2) is biologically different from 4+3=7 (Grade Group 3). Both sum to 7, but the dominant pattern determines the grade group and drives management — 4+3 tumors are more aggressive and typically require treatment rather than active surveillance.

3. The Foley catheter post-radical prostatectomy is non-negotiable. It maintains urinary drainage while the urethrovesical anastomosis heals over 7–14 days. Removing it early risks anastomotic dehiscence and urinary extravasation.

4. Kegel exercises begin as soon as the catheter is removed — not weeks later. Early pelvic floor muscle training reduces the duration and severity of post-prostatectomy stress urinary incontinence.

5. ADT causes bone loss — start calcium and vitamin D at initiation. Recommended: calcium 1,200 mg/day + vitamin D 800–1,000 IU/day; baseline DEXA scan; consider bisphosphonate or denosumab if T-score ≤ −2.5.

6. Hot flashes from ADT are not a fever. They are an expected result of castration-induced thermoregulatory dysregulation. Do not administer antipyretics; do address comfort measures.

7. Biochemical recurrence after RP is defined as PSA ≥0.2 ng/mL on two consecutive measurements. A single elevated PSA is not sufficient — two tests are required to confirm.

8. Leuprolide causes an initial testosterone flare for 1–2 weeks. Continuous GnRH receptor stimulation initially increases LH/FSH and testosterone before downregulation occurs. In patients with bone metastases, this flare can precipitate bone pain crisis or spinal cord compression. Co-administer an anti-androgen (bicalutamide) for 2–4 weeks at initiation to block the flare.

9. Degarelix does NOT cause testosterone flare. As a GnRH receptor antagonist, it directly blocks receptors without initial stimulation, achieving castrate testosterone within 3 days. It is preferred when rapid testosterone suppression is required or when flare is contraindicated (e.g., vertebral metastases at risk of cord compression).

10. Sipuleucel-T (Provenge) is an autologous cell-based immunotherapy — not conventional chemotherapy. The patient’s own antigen-presenting cells are leukapheresed, activated ex vivo against PAP antigen, and re-infused. Requires the patient to be ambulatory and have a life expectancy >6 months. It is not indicated for acute symptom palliation or rapidly progressing mCRPC.

11. Docetaxel: always premedicate with dexamethasone. Dexamethasone reduces hypersensitivity reactions and fluid retention associated with the Cremophor EL solvent. Monitor closely for febrile neutropenia — neutropenic nadir is typically days 8–10 post-infusion.

12. Abiraterone must always be co-prescribed with prednisone. CYP17A1 inhibition blocks cortisol synthesis, causing compensatory mineralocorticoid excess (hypertension, hypokalemia, fluid retention). Prednisone 5 mg BID suppresses this pathway. Never stop prednisone abruptly — adrenal insufficiency can result. Monitor BP, serum potassium, and liver function monthly.

13. Olaparib is indicated for BRCA1/2-mutated mCRPC. Primary toxicities are cytopenias (anemia, thrombocytopenia, neutropenia) — monitor CBC monthly. Contraindicated in pregnancy. Alert patients to the risk of myelodysplastic syndrome/AML (rare but serious) with prolonged use.

14. Anastomotic leak presents 5–7 days post-RP. Signs: fever, abdominal or pelvic pain, distension, leakage around (not through) the catheter, or sudden drop in catheter output with abdominal fullness. Report immediately — urinary extravasation causes chemical peritonitis.

15. Abiraterone is taken on an empty stomach. Food increases abiraterone absorption up to 10-fold, dramatically increasing systemic exposure and toxicity risk. This is a high-yield NCLEX pharmacology point: “no food for 2 hours before or 1 hour after.”

16. Low-residue diet during pelvic radiation reduces rectal toxicity. Reducing fiber and stool bulk decreases rectal distension during beam delivery, limiting anterior rectal wall dose. This is the first-line dietary intervention for radiation proctitis prevention.

Related articles

Oncology cluster:

• Breast cancer nursing: assessment, chemotherapy, and post-op care
• Colorectal cancer nursing: staging, surgery, and colostomy care
• Lung cancer nursing: staging, treatment, and nursing priorities
• Leukemia nursing: AML, ALL, CML, and CLL reference
• Lymphoma nursing: Hodgkin and non-Hodgkin reference

Genitourinary cluster:

• UTI nursing: cystitis, catheter-associated UTI, and NCLEX tips
• Pyelonephritis nursing: assessment and management
• Acute kidney injury nursing: stages, causes, and interventions
• CKD and ESRD nursing: stages, dialysis, and patient education